Latest news with #BrentGuerisoli
Yahoo
20-05-2025
- Business
- Yahoo
PNTG Q1 Earnings Call: Acquisition Momentum and Organic Growth Drive Outperformance
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts' consensus estimates. Is now the time to buy PNTG? Find out in our full research report (it's free). Revenue: $209.8 million vs analyst estimates of $201.5 million (33.7% year-on-year growth, 4.1% beat) Adjusted EPS: $0.27 vs analyst estimates of $0.24 (13.7% beat) Adjusted EBITDA: $16.37 million vs analyst estimates of $14.22 million (7.8% margin, 15.2% beat) Operating Margin: 6%, in line with the same quarter last year Free Cash Flow was -$21.11 million compared to -$2.85 million in the same quarter last year Sales Volumes rose 28.9% year on year (34.3% in the same quarter last year) Market Capitalization: $1.04 billion The Pennant Group's Q1 results were shaped by a combination of organic growth and integration of recent acquisitions, particularly in its Home Health and Hospice segment. CEO Brent Guerisoli pointed to the company's continued focus on leadership development, clinical excellence, and margin improvement as key drivers, with the Signature Healthcare transaction contributing to above-expectation performance. President John Gochnour highlighted strong growth in both new and existing operations, with home health admissions and hospice census rising notably. Looking ahead, management's guidance is influenced by the early progress in integrating acquired operations and a disciplined approach to further M&A. Guerisoli stated that the company is now 'pointing to the upper end of our 2025 guidance range,' reflecting sustained operational momentum and a robust pipeline of acquisition opportunities. Management also acknowledged ongoing monitoring of macroeconomic uncertainties and potential impacts on occupancy and pricing, especially in the senior living segment. Management attributed Q1's outperformance to successful acquisition transitions, organic growth in core segments, and strategic investments in leadership and clinical programs. Integration of the Signature Healthcare acquisition played a significant role in driving both revenue and operational gains. Acquisition Integration Success: The Signature Healthcare transition exceeded expectations, with effective onboarding of leaders and employees, quick adoption of Pennant's systems, and clinical integration leading to accelerated operational improvement. Home Health and Hospice Expansion: Organic and acquisition-driven growth in this segment resulted in higher admissions and average daily census, supported by investments in specialized care programs such as palliative and geriatric primary care. Senior Living Revenue Quality: Management focused on capturing higher-quality revenue in senior living, leading to an 11% increase in revenue per occupied room despite flat occupancy, and further margin improvement. Operational Efficiency and Clinical Outcomes: The company highlighted above-industry clinical quality ratings and reduced preventable hospitalizations, crediting disciplined local management and targeted clinical leadership development. M&A Pipeline and Transaction Update: Ongoing evaluation of further acquisition targets continues, including a pending asset purchase from UnitedHealth Group and Amedisys, with management emphasizing leadership readiness as a gating factor for future deals. Management's outlook for the remainder of the year centers on continued integration of recent acquisitions, disciplined pursuit of new opportunities, and cautious monitoring of macro-driven risks to occupancy and rate growth. Acquisition Execution: The pace and success of integrating newly acquired operations, such as Signature Healthcare and pending UnitedHealth-Amedisys assets, are expected to be primary contributors to revenue and margin trends. Organic Growth and Leadership Pipeline: Ongoing investment in local leadership and clinical programs is seen as critical for sustaining organic growth and improving profitability in both core segments. Macroeconomic Sensitivity: Management identified labor cost inflation and economic pressures on senior living residents as potential risks to occupancy and rate increases, requiring careful balance between pricing and census growth. Stephen Baxter (Wells Fargo): Asked about the factors driving the reacceleration of same-store growth in home health and hospice, with management attributing it to seasonal patterns and ongoing community adoption. Stephen Baxter (Wells Fargo): Requested further detail on which segment contributed most to the raised guidance and whether margin assumptions had changed, with leadership emphasizing balanced outperformance and continued momentum in both segments. Stephen Baxter (Wells Fargo): Inquired about the company's approach to evaluating the pending UnitedHealth-Amedisys asset deal, with CEO Guerisoli stressing leadership readiness and operational fit as key criteria for such transactions. Stephen Baxter (Wells Fargo): Sought clarification on the sustainability of strong rate growth in senior living amid economic uncertainty, with management noting the importance of revenue quality and partnerships with Medicaid and state programs. Stephen Baxter (Wells Fargo): Queried about hiring and retention trends, to which management reported positive hiring momentum, especially among nurses, but noted ongoing vigilance around labor costs and economic changes. Over the coming quarters, the StockStory team will focus on (1) the pace and effectiveness of newly acquired asset integrations, particularly the impact of the pending UnitedHealth-Amedisys transaction; (2) the sustainability of organic growth in home health admissions and hospice census; and (3) management's ability to balance senior living pricing initiatives with occupancy stability. Trends in labor inflation and execution on leadership development will also be closely watched as indicators of future performance. The Pennant Group currently trades at a forward P/E ratio of 26.7×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
The Pennant Group (NASDAQ:PNTG) Beats Expectations in Strong Q1
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts' consensus estimates. Is now the time to buy The Pennant Group? Find out in our full research report. The Pennant Group (PNTG) Q1 CY2025 Highlights: Revenue: $209.8 million vs analyst estimates of $201.5 million (33.7% year-on-year growth, 4.1% beat) Adjusted EPS: $0.27 vs analyst estimates of $0.24 (13.7% beat) Adjusted EBITDA: $16.37 million vs analyst estimates of $14.22 million (7.8% margin, 15.2% beat) Operating Margin: 6%, up from 5% in the same quarter last year Sales Volumes rose 28.9% year on year (34.3% in the same quarter last year) Market Capitalization: $928.4 million 'We are off to a strong start in 2025,' said Brent Guerisoli, the Company's Chief Executive Officer. Company Overview Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ:PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors. Sales Growth Reviewing a company's long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, The Pennant Group's 16.2% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers. The Pennant Group Quarterly Revenue Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. The Pennant Group's annualized revenue growth of 24.1% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. The Pennant Group Year-On-Year Revenue Growth We can better understand the company's revenue dynamics by analyzing its number of admissions, which reached 18,878 in the latest quarter. Over the last two years, The Pennant Group's admissions averaged 25.1% year-on-year growth. Because this number is in line with its revenue growth, we can see the company kept its prices fairly consistent. The Pennant Group Admissions This quarter, The Pennant Group reported wonderful year-on-year revenue growth of 33.7%, and its $209.8 million of revenue exceeded Wall Street's estimates by 4.1%. Looking ahead, sell-side analysts expect revenue to grow 13.4% over the next 12 months, a deceleration versus the last two years. Still, this projection is noteworthy and implies the market is forecasting success for its products and services.
Yahoo
11-04-2025
- Business
- Yahoo
Senior Health, Home Health & Hospice Stocks Q4 Recap: Benchmarking The Pennant Group (NASDAQ:PNTG)
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let's have a look at The Pennant Group (NASDAQ:PNTG) and its peers. The senior health, home care, and hospice care industries provide essential services to aging populations and patients with chronic or terminal conditions. These companies benefit from stable, recurring revenue driven by relationships with patients and families that can extend many months or even years. However, the labor-intensive nature of the business makes it vulnerable to rising labor costs and staffing shortages, while profitability is constrained by reimbursement rates from Medicare, Medicaid, and private insurers. Looking ahead, the industry is positioned for tailwinds from an aging population, increasing chronic disease prevalence, and a growing preference for personalized in-home care. Advancements in remote monitoring and telehealth are expected to enhance efficiency and care delivery. However, headwinds such as labor shortages, wage inflation, and regulatory uncertainty around reimbursement could pose challenges. Investments in digitization and technology-driven care will be critical for long-term success. The 7 senior health, home health & hospice stocks we track reported a strong Q4. As a group, revenues beat analysts' consensus estimates by 2%. In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results. Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ:PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors. The Pennant Group reported revenues of $188.9 million, up 29.4% year on year. This print exceeded analysts' expectations by 1.4%. Overall, it was a strong quarter for the company with a solid beat of analysts' sales volume estimates and full-year revenue guidance beating analysts' expectations. 'We are pleased to conclude a remarkable year, with strong performance in revenue, adjusted EBITDA, and adjusted earnings per share,' said Brent Guerisoli, the Company's Chief Executive Officer. The Pennant Group scored the fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street's published projections, leaving some wishing for even better results (analysts' consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 3.3% since reporting and currently trades at $24.69. Is now the time to buy The Pennant Group? Access our full analysis of the earnings results here, it's free. With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ:OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States. Option Care Health reported revenues of $1.35 billion, up 19.7% year on year, outperforming analysts' expectations by 4.9%. The business had an exceptional quarter with an impressive beat of analysts' full-year EPS guidance estimates. Option Care Health scored the biggest analyst estimates beat and highest full-year guidance raise among its peers. The market seems content with the results as the stock is up 1.1% since reporting. It currently trades at $33.02. Is now the time to buy Option Care Health? Access our full analysis of the earnings results here, it's free. With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living (NYSE:BKD) operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities. Brookdale reported revenues of $780.9 million, up 3.5% year on year, in line with analysts' expectations. It was a slower quarter as it posted a significant miss of analysts' EPS estimates. Brookdale delivered the weakest performance against analyst estimates in the group. Interestingly, the stock is up 5.1% since the results and currently trades at $5.58. Read our full analysis of Brookdale's results here. With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders. AdaptHealth reported revenues of $856.6 million, flat year on year. This result beat analysts' expectations by 3.3%. Overall, it was a strong quarter as it also put up a solid beat of analysts' EPS estimates and full-year EBITDA guidance slightly topping analysts' expectations. AdaptHealth had the slowest revenue growth and weakest full-year guidance update among its peers. The stock is up 4.7% since reporting and currently trades at $8.95. Read our full, actionable report on AdaptHealth here, it's free. Serving approximately 66,000 clients across 22 states with a focus on "dual eligible" Medicare and Medicaid beneficiaries, Addus HomeCare (NASDAQ:ADUS) provides in-home personal care, hospice, and home health services to elderly, chronically ill, and disabled individuals. Addus HomeCare reported revenues of $297.1 million, up 7.5% year on year. This print topped analysts' expectations by 2.7%. It was a very strong quarter as it also recorded an impressive beat of analysts' sales volume estimates and a decent beat of analysts' EPS estimates. The stock is down 5.6% since reporting and currently trades at $102.69. Read our full, actionable report on Addus HomeCare here, it's free. Thanks to the Fed's series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump's presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
07-03-2025
- Business
- Yahoo
Pennant Group to Participate in the 2025 Oppenheimer Annual Healthcare Conference
EAGLE, Idaho, March 07, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2025 Oppenheimer Co. Annual Healthcare MedTech & Services Conference on March 18, 2025. Brent Guerisoli, Chief Executive Officer, Lynette Walbom, Chief Financial Officer, and Kirk Cheney, Executive Vice President, will participate in a fireside chat on March 18, 2025 at 10:00 a.m. Eastern Time. A live webcast of the event will be accessible at the following address: About Pennant: The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 131 home health and hospice agencies and 60 senior living communities located throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at Contact Information The Pennant Group, Inc.(208) 506-6100ir@ SOURCE: The Pennant Group, in to access your portfolio
